"1"^^ . . "RIV/00064173:_____/11:00003481!RIV13-MZ0-00064173" . "1802-4475" . "Redukce toxicity prim\u00E1rn\u00ED l\u00E9\u010Dby pokro\u010Dil\u00E9ho hodgkinova lymfomu" . "CZ - \u010Cesk\u00E1 republika" . "Hodgkin\u016Fv lymfom (HL) je jedn\u00EDm z nejl\u00E9pe l\u00E9\u010Diteln\u00FDch n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED. Modern\u00EDmi l\u00E9\u010Debn\u00FDmi strategiemi je vyl\u00E9\u010Deno 85-95 % pacient\u016F. Do pop\u0159ed\u00ED za\u010Daly vystupovat pozdn\u00ED n\u00E1sledky l\u00E9\u010Dby, p\u0159edev\u0161\u00EDm kardiotoxicita a sekund\u00E1rn\u00ED malignity, na kter\u00E9 15 let po skon\u010Den\u00E9 terapii um\u00EDr\u00E1 v\u00EDce pacient\u016F ne\u017E na HL. C\u00EDlem v\u00FDzkumu je naj\u00EDt takovou terapii, kter\u00E1 by zajistila maxim\u00E1ln\u00ED kontrolu tumoru p\u0159i minimalizaci akutn\u00ED a dlouhodob\u00E9 toxicity. German Hodgkin Study Group (GHSG) prok\u00E1zala ve studii HD10 pro po\u010D\u00E1te\u010Dn\u00ED stadia HL mo\u017Enost redukce chemoterapie i radioterapie, bez sn\u00ED\u017Een\u00ED \u00FA\u010Dinnosti l\u00E9\u010Dby. Studie pro pokro\u010Dil\u00E1 stadia HD9 prok\u00E1zala v\u00FDborn\u00E9 v\u00FDsledky chemoterapie BEACOPP eskalovan\u00FD oproti konven\u010Dn\u00ED terapii ABVD, ale s vy\u0161\u0161\u00ED akutn\u00ED a dlouhodobou toxicitou. C\u00EDlem dal\u0161\u00EDch studi\u00ED GHSG pro pokro\u010Dil\u00E1 stadia (HD12, HD15 a nyn\u00ED aktivn\u00ED studie HD18) je sn\u00ED\u017Eit intenzitu chemoterapie a posoudit, zda je nutn\u00E1 n\u00E1sledn\u00E1 radioterapie. Pozitivn\u00ED v\u00FDsledky p\u0159in\u00E1\u0161\u00ED hodnocen\u00ED studie HD15, kde je testov\u00E1n v\u00FDznam FDG - PET p\u0159i indikaci radioterapie. Sou\u010Dasn\u00E1 studie HD18 sleduje pomoc\u00ED FDG - PET i \u010Dasnou odpov\u011B\u010F tumoru po 2 cyklech chemoterapie. Dal\u0161\u00ED nad\u011Bje jsou vkl\u00E1d\u00E1ny do nov\u00FDch biologick\u00FDch l\u00E9k\u016F, kter\u00E9 c\u00EDl\u00ED p\u0159\u00EDmo na receptory malign\u00EDch bun\u011Bk (monoklon\u00E1ln\u00ED protil\u00E1tky, inhibitory)." . . . "Redukce toxicity prim\u00E1rn\u00ED l\u00E9\u010Dby pokro\u010Dil\u00E9ho hodgkinova lymfomu" . . "1"^^ . . . . . "[EA424050A30D]" . "226086" . "I" . "Hodgkin\u016Fv lymfom (HL) je jedn\u00EDm z nejl\u00E9pe l\u00E9\u010Diteln\u00FDch n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED. Modern\u00EDmi l\u00E9\u010Debn\u00FDmi strategiemi je vyl\u00E9\u010Deno 85-95 % pacient\u016F. Do pop\u0159ed\u00ED za\u010Daly vystupovat pozdn\u00ED n\u00E1sledky l\u00E9\u010Dby, p\u0159edev\u0161\u00EDm kardiotoxicita a sekund\u00E1rn\u00ED malignity, na kter\u00E9 15 let po skon\u010Den\u00E9 terapii um\u00EDr\u00E1 v\u00EDce pacient\u016F ne\u017E na HL. C\u00EDlem v\u00FDzkumu je naj\u00EDt takovou terapii, kter\u00E1 by zajistila maxim\u00E1ln\u00ED kontrolu tumoru p\u0159i minimalizaci akutn\u00ED a dlouhodob\u00E9 toxicity. German Hodgkin Study Group (GHSG) prok\u00E1zala ve studii HD10 pro po\u010D\u00E1te\u010Dn\u00ED stadia HL mo\u017Enost redukce chemoterapie i radioterapie, bez sn\u00ED\u017Een\u00ED \u00FA\u010Dinnosti l\u00E9\u010Dby. Studie pro pokro\u010Dil\u00E1 stadia HD9 prok\u00E1zala v\u00FDborn\u00E9 v\u00FDsledky chemoterapie BEACOPP eskalovan\u00FD oproti konven\u010Dn\u00ED terapii ABVD, ale s vy\u0161\u0161\u00ED akutn\u00ED a dlouhodobou toxicitou. C\u00EDlem dal\u0161\u00EDch studi\u00ED GHSG pro pokro\u010Dil\u00E1 stadia (HD12, HD15 a nyn\u00ED aktivn\u00ED studie HD18) je sn\u00ED\u017Eit intenzitu chemoterapie a posoudit, zda je nutn\u00E1 n\u00E1sledn\u00E1 radioterapie. Pozitivn\u00ED v\u00FDsledky p\u0159in\u00E1\u0161\u00ED hodnocen\u00ED studie HD15, kde je testov\u00E1n v\u00FDznam FDG - PET p\u0159i indikaci radioterapie. Sou\u010Dasn\u00E1 studie HD18 sleduje pomoc\u00ED FDG - PET i \u010Dasnou odpov\u011B\u010F tumoru po 2 cyklech chemoterapie. Dal\u0161\u00ED nad\u011Bje jsou vkl\u00E1d\u00E1ny do nov\u00FDch biologick\u00FDch l\u00E9k\u016F, kter\u00E9 c\u00EDl\u00ED p\u0159\u00EDmo na receptory malign\u00EDch bun\u011Bk (monoklon\u00E1ln\u00ED protil\u00E1tky, inhibitory)."@cs . "Reduction of toxicity in first-line treatment of advanced stage Hodgkin lymphoma"@en . "Redukce toxicity prim\u00E1rn\u00ED l\u00E9\u010Dby pokro\u010Dil\u00E9ho hodgkinova lymfomu"@cs . . "Reduction of toxicity in first-line treatment of advanced stage Hodgkin lymphoma"@en . "Redukce toxicity prim\u00E1rn\u00ED l\u00E9\u010Dby pokro\u010Dil\u00E9ho hodgkinova lymfomu"@cs . "5" . "RIV/00064173:_____/11:00003481" . . "Markov\u00E1, Jana" . "BEACOPP; Hodgkin lymphoma"@en . "5" . . "Hodgkin lymphoma (HL) is one of the best curable malignant diseases. Modern therapeutic strategies can cure 85-95 % of patients. Late effects have become increasingly important, especially cardiotoxicity and second tumors, that cause more deaths than HL 15 years after completion of treatment. The goal of the research is to find the therapy that maximizes tumor control and minimizes acute and longterm toxicity. German Hodgkin Study Group (GHSG) proved the possibility to reduce chemotherapy and radiotherapy without reducing the effectiveness of treatment in the HD10 study for early stages of HL. HD9 study for advanced stages demonstrated excellent results of BEACOPP escalated chemotherapy compared to the conventional therapy ABVD, but BEACOPP escalated induced higher acute and long-term toxicity. The goal of subsequent GHSG studies for advanced stages (HD12, HD15 and ongoing active HD18 study) is to reduce the intensity of chemotherapy and to evaluate the significance of subsequent radiotherapy. The HD15 study tests the significance of FDG-PET for indication of radiotherapy. Current HD18 study tests by FDG-PET the early response of tumor after 2 cycles of chemotherapy. New biological drugs that target receptors on malignant cells (monoclonal antibodies, inhibitors) are awaited."@en . "3"^^ . "Onkologie" . . . .